about
Congenital Trypanosoma cruzi transmission in Santa Cruz, Bolivia.Interarm differences in systolic blood pressure and the risk of dementia and subclinical brain injuryRacial Disparities in Intravenous Recombinant Tissue Plasminogen Activator Use Persist at Primary Stroke Centers.Association of Ideal Cardiovascular Health With Vascular Brain Injury and Incident Dementia.Association of descending thoracic aortic plaque with brain atrophy and white matter hyperintensities: The Framingham Heart Study.Stroke as the Initial Manifestation of Atrial Fibrillation: The Framingham Heart Study.Overweight, Obesity, and Survival After Stroke in the Framingham Heart Study.Sugar- and Artificially Sweetened Beverages and the Risks of Incident Stroke and Dementia: A Prospective Cohort Study.Sugary beverage intake and preclinical Alzheimer's disease in the community.Revised Framingham Stroke Risk Profile to Reflect Temporal Trends.Lacunar Infarcts and Intracerebral Hemorrhage Differences: A Nested Case-Control Analysis in the FHS (Framingham Heart Study).Associations between social relationship measures, serum brain-derived neurotrophic factor, and risk of stroke and dementia.Sleep architecture and the risk of incident dementia in the community.Heart of the Matter.Vascular risk at younger ages most strongly associates with current and future brain volumeAuthor response: Sleep architecture and the risk of incident dementia in the communityRace and Science: Using a Comprehensive Interdisciplinary Approach to Address Complex IssuesAPOE and the Association of Fatty Acids With the Risk of Stroke, Coronary Heart Disease, and MortalityPlasma total-tau as a biomarker of stroke risk in the communityAssociation of CD14 with incident dementia and markers of brain aging and injuryTemporal Trends in Ischemic Stroke Incidence in Younger Adults in the Framingham StudyAssessment of Plasma Total Tau Level as a Predictive Biomarker for Dementia and Related EndophenotypesOptimization of Resources and Modifications in Acute Ischemic Stroke Care in Response to the Global COVID-19 Pandemic
P50
Q33754264-7BF64545-204E-4130-B836-93709C527130Q36827380-0EFA4CC4-A721-4B8D-BE81-4919D7085E08Q36836040-C59857CB-D31F-4EE3-ACD7-A7EB87A20CD8Q37221583-606579FA-D60D-4ADB-95B2-60403F5E8F3AQ38695707-D1D2DC19-0A23-4E73-8AC6-476B869B1DCFQ39023561-D7780694-0E71-4067-965F-5695AE028A81Q40146696-36329E9D-9ABD-4BDF-A206-1C21958FE850Q40233683-85AAC8C6-33DD-4B06-9EA8-A8CDD9662B3AQ40301519-E046D1DA-563C-43BF-A47D-9CC3D02F635FQ40350544-31EF2E2D-6371-4EDF-9E17-CAF898BD36C9Q40410968-A3F98C1D-618D-4B84-B8C3-A3F506C0E56AQ42655586-4EBDB5B1-2960-454E-A2A8-4DE5CF4513BEQ47693820-42277760-3938-4637-93DD-C49302FE0ABAQ48154957-E7C31F74-56BE-4AA5-8479-D4784D94BAC9Q57154957-C66D8BA5-10D1-4BE0-90A1-06CDFE78C41DQ57618873-102DB61A-6FF2-42B8-BDA9-2B2D48DFBB7EQ57619109-25591FAF-B0AF-4149-80A2-FD05959BF220Q90667979-24CA3673-4DDF-4235-AEA5-93ED8185C8CEQ91603968-CBE5D443-4010-4E04-982A-DC31A50FE39DQ91824066-0F2FB757-855D-4D26-902D-BC3A03EC14F0Q91987471-B91DF617-5ADD-477C-B849-A8AF86D1C3BDQ92103818-166170E4-6821-452C-BCCE-D209E7E33D67Q95605984-2967A939-8FFC-4ED4-A043-344B93C47DCD
P50
description
researcher
@en
wetenschapper
@nl
հետազոտող
@hy
name
Hugo J Aparicio
@ast
Hugo J Aparicio
@en
Hugo J Aparicio
@es
Hugo J Aparicio
@nl
Hugo J Aparicio
@sl
type
label
Hugo J Aparicio
@ast
Hugo J Aparicio
@en
Hugo J Aparicio
@es
Hugo J Aparicio
@nl
Hugo J Aparicio
@sl
altLabel
Hugo Aparicio
@en
prefLabel
Hugo J Aparicio
@ast
Hugo J Aparicio
@en
Hugo J Aparicio
@es
Hugo J Aparicio
@nl
Hugo J Aparicio
@sl
P1053
M-2051-2014
P106
P1153
56826212400
P2002
hugojaparicio
P21
P31
P3829
P3835
hugo-j-aparicio
P496
0000-0001-8584-1455